Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$550B
P/E ratio
26×
Div yield
2.3%
Revenue
$94B
Free cash flow
$20B
Rev. growth
+6%
Div streak
64 yrs
Profit margin
~22%
In plain English
Johnson & Johnson is a healthcare giant in two halves: Innovative Medicine, a top-tier drugmaker behind blockbuster cancer (Darzalex, Carvykti) and immunology (Tremfya, Stelara) medicines, and MedTech, which builds surgical, cardiovascular and orthopaedic devices used in operating rooms worldwide. After spinning off its consumer-products arm as Kenvue in 2023, J&J is now a pure-play prescription-medicine and medical-device company funded by a string of large acquisitions.
In simple terms
What Johnson & Johnson really sells
Johnson & Johnson is a healthcare giant in two halves: Innovative Medicine, a top-tier drugmaker behind blockbuster cancer (Darzalex, Carvykti) and immunology (Tremfya, Stelara) medicines, and MedTech, which builds surgical, cardiovascular and orthopaedic devices used in operating rooms worldwide. After spinning off its consumer-products arm as Kenvue in 2023, J&J is now a pure-play prescription-medicine and medical-device company funded by a string of large acquisitions.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.